Adopt AWaRe: Handle antibiotics with care.

2.4m

Superbug infections could cost the lives of around 2.4 million people in Europe, North America and Australia over the next 30 years if no action is taken (OECD).

40-60%

In selected low- and middle-income countries, the proportion of resistant infections ranges from 40-60% compared to an average of 17% for OECD countries (OECD).

671,689

In 2015, there were 671,689 infections with antibiotic-resistant bacteria recorded in the EU (The Lancet).

AWaRe is a useful tool to reduce antimicrobial resistance and ensure access.

Access

Which indicates the antibiotic of choice for each of the 25 most common infections. These antibiotics should be available at all times, affordable and quality-assured.

Watch

Which includes most of the “highest-priority critically important antimicrobials” for human medicine and veterinary use. These antibiotics are recommended only for specific, limited indications

Reserve

Antibiotics that should only be used as a last resort when all other antibiotics have failed.

The overall goal is to reduce the use of Watch Group and Reserve Group antibiotics (the antibiotics most crucial for human medicine and at higher risk of resistance), and to increase the use of Access antibiotics where availability is low.

The right antibiotic at the right time.

We can reduce or even reverse antibiotic resistance by using antibiotics more responsibly. But how do we do that and still ensure that patients are treated effectively? WHO has developed a tool to help global, regional and national decision-making on which antibiotics to use when.

See More
As part of the 2017 Essential Medicines List , WHO carried out a comprehensive review of antibiotics and introduced a new categorization to guide prescriptions and treatment while monitoring consumption. The overall goal is to reduce the use of Watch Group and Reserve Group antibiotics (the antibiotics most crucial for human medicine and at higher risk of resistance), and to increase the use of Access antibiotics where availability is low.

By 2023, 60% of all antibiotics consumed must come from Access - the group of antibiotics at lowest risk of resistance.

See More
Evidence shows that to promote responsible use of antibiotics, Access antibiotics should make up at least 60% of national consumption. This will not only result in better use of antibiotics but also in reduced costs and increased access. Reaching this threshold by 2023 will contribute to countries’ achieving health related targets of the sustainable development goals.

We must act together with urgency.

What happens if we fail to tackle antimicrobial resistance?

Why should countries adopt AWaRe as a benchmark for optimal use?

What can countries do to implement AWaRe?